Method for detecting quantity of first structure and quantity of second structure

The method of simultaneous detection of labels bound to viral capsids and nucleic acids addresses the inefficiencies in existing viral particle detection, providing accurate and efficient quantification of complete and empty particles without the need for costly purification.

WO2024241780A1PCT designated stage expired Publication Date: 2024-11-28OSAKA UNIVERSITY
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/015380
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2024-04-18
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods for detecting the concentration of complete and empty viral particles in viral vector products are inefficient, prone to errors, and require time-consuming and costly purification processes, such as ultracentrifugation, which is not feasible for all settings.

Method used

A method involving the simultaneous detection of a first label bound to a viral capsid and a second label bound to the nucleic acid, using fluorescent or radioactive labels, allows for the calculation of the ratio of viral capsids containing nucleic acid to those not containing nucleic acid without the need for separate purification steps.

Benefits of technology

This method reduces detection time and errors, eliminates the need for costly purification, and enables accurate quantification of viral capsids and genome titers in unpurified samples, improving the efficiency and reliability of viral vector analysis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024015380_28112024_PF_FP_ABST
    Figure JP2024015380_28112024_PF_FP_ABST
Patent Text Reader

Abstract

[Problem] To provide a method for detecting the quantity of a first structure and the quantity of a second structure, the method comprising a step for detecting the quantity of a bonded first label and the quantity of a bonded second label together. [Solution] Provided is a method for detecting the quantity of a first structure and the quantity of a second structure, the method comprising: a step for bonding a first label to a first structure; a step for releasing a second structure from the first structure; a step for boding a second label to the second structure; and a step for detecting the quantity of the bonded first label and the quantity of the bonded second label together, wherein the second structure is included in the first structure, and the first label and the second label can be detected together, but are different.
Need to check novelty before this filing date? Find Prior Art

Description

Method for detecting an amount of a first structure and an amount of a second structure

[0001] The present invention relates to a method for detecting the amount of a first structure and the amount of a second structure, a method for assessing the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid, and kits for use in these methods.

[0002] Viral vectors used in gene therapy and other applications are known to produce both active (containing DNA, etc.) particles (complete particles) and inactive (containing no DNA, etc.) particles (empty particles) during production. Because it is difficult to completely separate these two types of particles through purification, viral vector products typically contain both complete and empty particles. The concentrations and ratios of complete and empty particles are related to the efficacy and safety of viral vectors, and therefore must be evaluated not only at the time of release but also during the development of manufacturing methods (Non-Patent Document 1: Werle AK, Powers TW, Zobel JF, et al. Comparison of analytical techniques to quantitate the capsid content of adeno-associated viral vectors. Mol Ther Methods Clin Dev. 2021;23:254-262. Published 2021 Sep 1. doi:10.1016 / j.omtm.2021.08.009).

[0003] Until now, total particle concentration (complete and empty particles) has been determined using enzyme-linked immunosorbent assay (ELISA), and nucleic acid concentration has been quantified using polymerase chain reaction (PCR) to estimate complete particle concentration (Non-Patent Document 2: https: / / darkhorseconsultinggroup.com / wp-content / uploads / 2022 / 05 / DHC_Proposed-DRAFT-Guidance-for-FDA-Consideration.pdf). This method involves the combination of two different mechanisms, which can lead to errors in the complete / empty particle ratio, and concerns about the need to quantify complete and empty particles using samples that are not strictly identical. Furthermore, performing two measurements requires time and effort. In addition to the combination of ELISA and PCR, other methods such as ultracentrifugation and chromatography have been proposed to separate and quantify complete particles and empty particles, but these have limitations such as the need for prior purification when used in analysis during manufacturing method development, etc. In addition, ultracentrifugation requires expensive equipment and skilled techniques.

[0004] Werle AK, Powers TW, Zobel JF, et al. Comparison of analytical techniques to quantitate the capsid content of adeno-associated viral vectors. Mol Ther Methods Clin Dev. 2021;23:254-262. Published 2021 Sep 1. doi:10.1016 / j.omtm.2021.08.009https: / / darkhorseconsultinggroup.com / wp-content / uploads / 2022 / 05 / DHC_Proposed-DRAFT-Guidance-for-FDA-Consideration.pdf

[0005] However, conventional methods for detecting the amount of a first label bound to a first structure and the amount of a second label bound to a second structure, or for assessing the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid, require separate detection of the amount of the first structure or viral capsid and the amount of the second structure or nucleic acid, respectively. Therefore, there is a need for a method for jointly detecting the amount of the first label bound to a first structure or viral capsid and the amount of the second label bound to a second structure or nucleic acid.

[0006] A method for detecting the amount of a first structure and the amount of a second structure according to the present invention comprises the steps of binding a first label to the first structure, releasing the second structure from the first structure, binding a second label to the second structure, and jointly detecting the amount of bound first label and the amount of bound second label, wherein the second structure is contained within the first structure, and the first label and the second label are different but can be detected together.

[0007] The method of the present invention for assessing the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid comprises the steps of immobilizing viral capsids on a support, indirectly binding a first label to the viral capsids via an antibody that binds to the viral capsids, washing away the unbound first label, releasing nucleic acid from the viral capsids, binding a second label to the released nucleic acid, detecting the amount of the bound first label and the amount of the bound second label together, and calculating or determining the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid based on the amount of the bound first label and the amount of the bound second label, wherein the nucleic acid is encapsulated in the viral capsids, and the first label and the second label can be detected together but are different.

[0008] A kit according to the present invention comprises a first label for a first structure, a second label for a second structure, and instructions for jointly detecting the amount of bound first label and the amount of bound second label, wherein the second structure is contained within the first structure, and the first and second labels are different but can be detected together.

[0009] That is, the present invention provides the following: [1] A method for detecting the amount of a first structure and the amount of a second structure, the method comprising: binding a first label to the first structure; releasing a second structure from the first structure; binding a second label to the second structure; and jointly detecting the amount of the bound first label and the amount of the bound second label, wherein the second structure is contained in the first structure, and the first label and the second label can be detected together but are different. [2] The method of [1], further comprising a step of washing away the first label that is not bound to the first structure. [3] The method of [2], wherein the step of washing away the first label that is not bound to the first structure is performed after the step of binding the first label to the first structure and before the step of releasing the second structure from the first structure and the step of binding the second label to the second structure. [4] The method of [1], further comprising a step of immobilizing the first structure on a support. [5] The method of [1], wherein the first structure is composed of a protein, a lipid, a polymer, or a combination thereof. [6] The method of [1], wherein the first structure is selected from the group consisting of a virus particle, a virus capsid, a liposome, a lipid nanoparticle (LNP), and a polymer particle. [7] The method of [6], wherein the virus is selected from the group consisting of an adeno-associated virus (AAV), a retrovirus, a lentivirus, and an adenovirus. [8] The method of [1], wherein the second structure is composed of a nucleic acid, a protein, a compound, or a combination thereof. [9] The method of [8], wherein the second structure is selected from the group consisting of DNA, single-stranded DNA (ssDNA), self-complementary DNA (scDNA), RNA, miRNA, lncRNA, a peptide, an antibody, a detection compound, and a drug.

[10] The method of [1], wherein the first label and the second label are fluorescent dyes or radioactive labels.

[11] The method of [1], wherein the step of binding a first label to a first structure comprises indirectly binding via one or more molecules that specifically bind to the first structure, such as an antibody, an antibody fragment, a lectin, an aptamer, a ligand, a peptide, or a cyclic peptide, or comprises indirectly binding via the molecule that specifically binds to the first structure and a secondary antibody that specifically binds to the molecule.

[12] The method of [1], wherein the step of jointly detecting the amount of bound first label and the amount of bound second label comprises jointly detecting them using a single device or detector.

[13] The method of [1], wherein the amount of first structure and the amount of second structure are calculated or determined based on the amount of bound first label and the amount of bound second label.

[14] The method of [1], further comprising calculating or determining the ratio of first structures that include the second structure to first structures that do not include the second structure.

[15] A method for assessing the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid, the method comprising the steps of: immobilizing viral capsids on a support; indirectly binding a first label to the viral capsids via an antibody that binds to the viral capsid; washing away unbound first label; releasing nucleic acid from the viral capsids; binding a second label to the released nucleic acid; detecting the amount of bound first label and the amount of bound second label together; and calculating or determining the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid based on the amount of bound first label and the amount of bound second label, wherein the nucleic acid is encapsulated in the viral capsids, and the first label and the second label can be detected together but are different.

[16] A detection kit comprising: a first label for a first structure; a second label for a second structure; and instructions for jointly detecting the amount of bound first label and the amount of bound second label, wherein the second structure is contained within the first structure; and the first label and the second label are different but can be detected together.

[0010] The method of the present invention includes a step of jointly detecting the amount of a first label bound to a first structure and the amount of a second label bound to a second structure. As a result, compared to a method including a step of separately detecting the amount of a first label bound to a first structure and the amount of a second label bound to a second structure, the method of the present invention can, for example, reduce the time or effort required to detect the amount of the first structure and the amount of the second structure, reduce the cost of detecting the amount of the first structure and the amount of the second structure, reduce the detection error of the amount of the first structure and the amount of the second structure, eliminate the need to purify the first structure or the second structure from a sample containing contaminants, or enable the amount of the first structure and the second structure to be detected at low concentrations.

[0011] Figure 1 shows a simplified flowchart of one embodiment of the method of the present invention. Figure 2 shows a simplified flowchart of one embodiment of the method of the present invention. Test results from Example 1 using AAV8. Test results from Example 2 using AAV2. Test results from Example 3 using a mixture of AAV2 and AAV8. Test results from Example 4 using Quantifluor. Test results from Example 5 using AAV2 containing ssDNA and AAV2 containing scDNA. Test results from Example 6 using conventional wavelengths of 495 nm and 535 nm and our wavelengths of 500 nm and 535 nm. Test results from Example 7 using clear plates and black plates. Applicability of dFLISA to analysis of unpurified samples. (A) Quantification of capsid titer. (B) Quantification of genome titer. (C) Percentage of intact particles. Various dilution factors for spike recovery were evaluated by comparing experimental values ​​determined by dFLISA with predicted values ​​determined by AUC analysis. The predicted values ​​obtained from AUC were compared with the dFLISA values ​​for three parameters: capsid titer, genome titer, and FP / EP ratio. Results are the average of duplicate wells. H represents high-spiked, M represents medium-spiked, and L represents low-spiked. All data are shown as the mean and standard deviation (n = 2). Evaluation of the dFLISA's ability to quantify unpurified samples. The AAV8 content in unpurified samples was analyzed using three methods: dFLISA, ELISA, and dPCR. dFLISA quantified capsid and genome titers and calculated the FP / EP ratio of AAV8 content in unpurified samples. ELISA was used to quantify capsid content, with SD calculated from independent measurements (n = 2). dPCR was used to determine genome content in unpurified samples, with SD calculated from three independent measurements (n = 3). The complete particle ratio was calculated using dPCR / ELISA. All data shown in these experiments are the average of replicate measurements for each assay. Comparison of fluorescence intensity of AAVs with different genome lengths. The fluorescence intensity of ssDNA of different lengths obtained from AGE was divided by the MP results (relative area (concentration)) and plotted against the length of the ssDNA ladder standard.

[0012] In one embodiment, the present invention provides a method for detecting the amount (or concentration) of a first structure and the amount (or concentration) of a second structure, the method comprising the steps of binding a first label to the first structure, binding a second label to the second structure, and jointly detecting the amount of bound first label and the amount of bound second label, wherein the first label and the second label are different but can be detected together.

[0013] In one embodiment, the present invention provides a method for detecting the amount (or concentration) of a first structure and the amount (or concentration) of a second structure, the method comprising the steps of binding a first label to the first structure, releasing a second structure from the first structure, binding a second label to the second structure, and jointly detecting the amount (or concentration) of the bound first label and the amount (or concentration) of the bound second label, wherein the second structure is contained within the first structure, and the first label and the second label are different but can be detected together.

[0014] In one embodiment, the present invention provides a method for assessing the ratio of viral capsids that contain nucleic acid to viral capsids that do not contain nucleic acid, the method comprising the steps of immobilizing viral capsids on a support, indirectly binding a first label to the viral capsids via an antibody that binds to the viral capsids, washing away the unbound first label, releasing nucleic acid from the viral capsids, binding a second label to the released nucleic acid, jointly detecting the amount (or concentration) of the bound first label and the amount (or concentration) of the bound second label, and calculating or determining the ratio of viral capsids that contain nucleic acid to viral capsids that do not contain nucleic acid based on the amount (or concentration) of the bound first label and the amount (or concentration) of the bound second label, wherein the nucleic acid is encapsulated in the viral capsids, and the first label and the second label can be detected together but are different.

[0015] In one embodiment, the present invention provides a kit comprising a first label for a first structure, a second label for a second structure, and instructions for jointly detecting the amount (or concentration) of the bound first label and the amount (or concentration) of the bound second label, wherein the second structure is contained within the first structure, and the first label and the second label are different but can be detected together.

[0016] As used herein, a "first structure" may be composed of any material or substance, such as a protein, lipid, or polymer, or a combination thereof, and may be, for example, a virus particle, a virus capsid, a liposome, a lipid nanoparticle (LNP), or a polymer particle. A "first structure" may be used as a tool for treating or diagnosing a disease or for in vivo gene transfer. A "first structure" may encompass a "second structure." A "first structure" may not encompass a "second structure." A "first structure" may be a "first structure" that encompasses a "second structure" and / or a "first structure" that does not encompass a "second structure." A "first structure" may be bound to a "second structure." A "first structure" may not be bound to a "second structure." A "first structure" may be a "first structure" that is bound to a "second structure" and / or a "first structure" that is not bound to a "second structure."

[0017] Viruses include any virus, such as adeno-associated viruses (AAV), retroviruses, lentiviruses, and adenoviruses, and those viruses with modified viral capsid proteins. AAV includes natural adeno-associated viruses or recombinant adeno-associated viruses. AAV includes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, and AAV-11.

[0018] Adeno-associated virus (AAV) belongs to the Parvoviridae family. The AAV genome consists of a linear, single-stranded DNA molecule of approximately 4.7 kilobases (kb) and consists of two major open reading frames encoding nonstructural Rep (replication) proteins and structural Cap (capsid) proteins. AAV-derived recombinant vectors are used as tools for disease treatment or diagnosis. Adeno-associated virus (AAV)-derived viral vectors are used as tools for in vivo gene transfer due to their superior in vivo efficiency, broad tissue tropism, and excellent safety profile compared to other vectors. Active (DNA-containing) adeno-associated virus (AAV) particles (complete particles) may be used as tools for disease treatment or diagnosis or in vivo gene transfer.

[0019] As used herein, a "second structure" may be composed of any material or substance, such as a nucleic acid, a protein, a compound, or a combination thereof, such as DNA, single-stranded DNA (ssDNA), self-complementary DNA (scDNA), RNA, miRNA, lncRNA, peptides, antibodies, detection compounds, and drugs. "Second structures" include those that can be used for the treatment, prevention, or diagnosis of diseases, for example. Diseases may include cancer, autoimmune diseases, infectious diseases, and the like. "Second structures" may be transgenes, transcriptional regulators, gene therapy agents, nucleic acids encoding small molecules, nucleic acids encoding antibodies, nucleic acids encoding proteins, small interfering RNAs, antisense RNAs, ribozymes, nucleic acids encoding therapeutic proteins, nucleic acids for genome editing, nucleic acids for gene recombination, and microRNAs (miRNAs). The "second structure" may be contained within the "first structure." The "second structure" may be bound to the "first structure."

[0020] As used herein, the term "encompassing" in the context of "a second structure is enclosed in a first structure," "a first structure encompassing a second structure," or "a first structure not encompassing a second structure" refers to a structure or state in which a first structure encloses a second structure. For example, "a second structure is enclosed in a first structure" means that the second structure is present inside the first structure. The second structure may or may not be attached to the inner surface of the first structure. For example, a "first structure not encompassing a second structure" is a first structure in which the second structure is not present inside the first structure.

[0021] As used herein, the term "label" includes any detectable signal source, such as fluorescent, visible, optical, colorimetric, dye, enzyme, GCMS tag, avidin, biotin, and radioactive substances (radioactive labels and radiopaque labels, etc.). The term "label" also includes various molecules, such as dyes (fluorescent dyes) that emit fluorescent signals, radioactive labels, molecules that emit MRI signals, and molecules that emit ultrasound signals, as well as various microparticles, such as iron oxide microparticles, gold microparticles, gold nanorods, and microparticles of metals or metal oxides, such as platinum and silver. The "label" can be detected by a device or detector based on the properties, activity, intensity, or quantity of the label. Those skilled in the art can appropriately select the label, device, or detector based on the properties, activity, intensity, or quantity of the label. The "label" may be a detectable signal source alone, or may be a protein, antibody, peptide, probe, or the like, that has a detectable signal source.

[0022] The fluorescent dye may be any dye that emits a fluorescent signal, for example, commercially available fluorescent dyes, known fluorescent dyes, Alexa Fluor (registered trademark) 647, SYBR (registered trademark) Gold, SYBR (registered trademark) green, QuantiFluor (registered trademark) ssDNA Dye Systems, fluorescein, Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 647, Alexa Fluor 680, Alexa Examples of suitable fluorescent dyes include Fluor 700, Alexa Fluor 750, Alexa Fluor 790, SYBR Gold, SYBR Green I, SYBR Green II, SYBR Safe, or QuantiFluor ssDNA Dye Systems (QuantiFluor dsDNA, RNA, or ssDNA System). Fluorescent dyes can be detected by optical sensors, photodetectors, microscopes, devices, or detectors based on the wavelength, characteristics, activity, intensity, or amount of the fluorescent signal or fluorescent dye. Those skilled in the art can appropriately select optical sensors, photodetectors, microscopes, devices, or detectors based on the wavelength, characteristics, activity, intensity, or amount of the fluorescent signal or fluorescent dye.

[0023] Radioactive labels include any label that emits radioactive substances, for example, commercially available radioactive labels, known radioactive labels, F, P, S, I, I, Cu, or Cu. Radioactive labels can be detected by a radiation or radioactivity sensor, a radiation or radioactivity detector, a device, or a detector, etc., based on the properties, activity, strength, or amount of the radioactive label. Those skilled in the art can appropriately select a radiation or radioactivity sensor, a radiation or radioactivity detector, a device, or a detector, based on the properties, activity, strength, or amount of the radioactive label.

[0024] As used herein, a "first label for a first structure" or a "first label" is directly or indirectly bound to a first structure. A "first label for a first structure" or a "first label" may be indirectly bound to a first structure via one or more molecules that specifically bind to the first structure, such as an antibody, an antibody fragment, a lectin, an aptamer, a ligand, a peptide, or a cyclic peptide. A "first label for a first structure" or a "first label" may be indirectly bound to a first structure via an antibody that specifically binds to the first structure and a secondary antibody that specifically binds to the antibody. When the method includes a step of releasing a second structure from the first structure, a "first label for a first structure" or a "first label" may be a label that is not, or is not easily, destroyed or disabled in the step. When the method includes a step of washing away first labels that are not bound to the first structures, the "first label on the first structure" or "first label" may be a label that is not destroyed or disabled, or is unlikely to be destroyed or disabled, in the step. The first structure may have one or more additional labels bound to it in addition to the "first label on the first structure" or "first label." The "first label on the first structure" or "first label" may be a fluorescent dye or a radioactive label. The "first label for the first structure" or the "first label" may be, for example, a commercially available fluorescent dye, a known fluorescent dye, Alexa Fluor (registered trademark) 647, fluorescein, Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 647, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor 750, Alexa Fluor 594, or the like. 790, or TMB (3,3',5,5'-tetramethylbenzidine).Those skilled in the art can appropriately select a "first label for a first structure" or a "first label" based on the characteristics of the first structure, the first label, the device, the detector, or the detection results, etc.

[0025] As used herein, a "secondary label for a second structure" or a "secondary label" is directly or indirectly bound to a second structure. A "secondary label for a second structure" or a "secondary label" may be indirectly bound to a second structure via one or more molecules that specifically bind to the second structure, such as an antibody, an antibody fragment, a lectin, an aptamer, a ligand, a peptide, or a cyclic peptide. A "secondary label for a second structure" or a "secondary label" may be indirectly bound to a second structure via an antibody that specifically binds to the second structure and a secondary antibody that specifically binds to the antibody. A "secondary label for a second structure" or a "secondary label" may be a label that generates a different detectable signal when bound to a second structure compared to when not bound to the second structure. A "secondary label for a second structure" or a "secondary label" may be a label that generates a detectable signal when bound to a second structure but does not generate a detectable signal when not bound to the second structure. A "second label on a second structure" or "second label" may be a label that generates a greater, less, or a different detectable signal when bound to a second structure than when not bound to the second structure. The second structure may have one or more additional labels attached to it in addition to the "second label on a second structure" or "second label." A "second label on a second structure" or "second label" may be a fluorescent dye or a radioactive label.The "second label for the second structure" or the "second label" may be, for example, a commercially available fluorescent dye, a known fluorescent dye, SYBR® Gold, SYBR® green, QuantiFluor® ssDNA Dye Systems, fluorescein, SYBR Gold, SYBR® Green I, SYBR® Green II, SYBR Safe, QuantiFluor ssDNA Dye Systems (QuantiFluor dsDNA, RNA or ssDNA System), SYPRO® orange, Thioflavin T, SYPRO orange, SYPRO Tangerine, SYPRO® Fluorescein, SYBR ... Red, SYPRO Ruby, SYTOX® Blue, SYTOX® Green, SYTOX® Orange, SYTOX® Red, SYTOX® AADvanced®, or Hoechst, for example, Hoechst 33343 and 33258. Those skilled in the art can appropriately select a "second label for a second structure" or a "second label" based on the characteristics of the second structure, the second label, the device, the detector, or the detection results, etc.

[0026] As used herein, a "first label for a first structure" or a "first label" and a "second label for a second structure" or a "second label" are different labels that can be detected together. For example, the "first label" and the "second label" are labels that can be detected together using one or more devices or detectors, and detection results for the respective labels of the first structure and the second structure can be obtained. For example, the "first label" and the "second label" are fluorescent dyes that emit different fluorescent signals and can be detected together using one or more microscopes, devices, or detectors, and detection results for the fluorescent signals of the respective fluorescent dyes of the first label and the second label can be obtained, for example, based on their respective wavelengths. For example, the "first label" and the "second label" can be detected together using one device or detector. Those skilled in the art can appropriately select the "first label" and the "second label" based on the characteristics of the first structure, the second structure, the first label, the second label, the device, the detector, or the detection results.

[0027] As used herein, in the context of "jointly detecting the amount of a bound first label and the amount of a bound second label," "jointly detecting" means detecting two or more substances to be detected in one space or location containing them (e.g., one sample, one container, or one well in a plate). For example, "jointly detecting the amount of a bound first label and the amount of a bound second label" may mean detecting the amounts of the first label and the second label in one space or location containing the bound first label and the bound second label (e.g., one sample, one container, or one well in a plate). For example, "detecting the amount of bound first label and the amount of bound second label together" can mean detecting the amounts of each of the first label and the second label simultaneously, or sequentially or sequentially (e.g., detecting the amounts of each of the first label and the second label simultaneously, detecting the amount of the first label first and then the amount of the second label, or detecting the amount of the second label first and then the amount of the first label).

[0028] As used herein, a "kit" includes a first label for a first structure, a second label for a second structure, and instructions for jointly detecting the amount of bound first label and the amount of bound second label. The "kit" may be a kit for use in any of the methods for detecting the amount of a first structure and the amount of a second structure described herein. The "kit" may further include any peptide, protein, antibody, nucleic acid, additional label, enzyme, substrate, reagent, buffer, salt, plate, container, or the like.

[0029] As used herein, "about" means approximately, or around. When used in conjunction with a numerical range, "about" may extend that range above and below the boundaries of the stated numerical values. "About" may refer to a numerical range of ±10% of the stated numerical value.

[0030] In one embodiment, the method of the present invention includes a step of immobilizing or binding the first structure and / or the second structure to a support before or after the step of binding the first label and / or the step of binding the second label. The first structure and / or the second structure may be indirectly bound to the support via one or more substances, such as molecules that specifically bind to the first structure and / or the second structure, such as antibodies, antibody fragments, lectins, aptamers, ligands, peptides, or cyclic peptides. The step of indirectly immobilizing the first structure and / or the second structure to the support may include (i) attaching to the support a substance capable of binding to the support and to the first structure and / or the second structure, e.g., a molecule that specifically binds to the first structure and / or the second structure, such as an antibody, antibody fragment, lectin, aptamer, ligand, peptide, or cyclic peptide, (ii) washing the support with a washing buffer, (iii) coating the support with a blocking buffer, (iv) washing the support with a washing buffer, (v) binding the first structure and / or the second structure to the substance, e.g., molecule, e.g., antibody, antibody fragment, lectin, aptamer, ligand, peptide, or cyclic peptide, and / or (vi) washing the support with a washing buffer. For example, the step of immobilizing the first structure and / or the second structure to the support can hold or maintain the first structure and / or the second structure on the support. For example, the step of immobilizing the first structure and / or the second structure on the support allows unwanted materials to be washed from the support, including buffer and materials that are not bound to the support, such as molecules, e.g., antibodies, antibody fragments, lectins, aptamers, ligands, peptides, or cyclic peptides, unbound first structure and / or unbound second structure, etc.

[0031] The support includes any plate or vessel, such as a petri dish, microplate, or vessel for culture, measurement, or ELISA. The support may be of any color, such as transparent, translucent, white, or black. The support may be white for chemiluminescence detection or black for fluorescence or chemiluminescence detection. The support may be a black microplate for fluorescent dye detection.

[0032] In one embodiment, the method of the present invention comprises a step of binding a first label to a first structure and a step of binding a second label to a second structure. The steps of binding the first label to the first structure and the second label to the second structure may be performed in any order or simultaneously. The steps of binding the first label to the first structure and the second label to the second structure may be performed by first binding the first label to the first structure and then binding the second label to the second structure. The steps of binding the first label to the first structure and the second label to the second structure may be performed by first binding the second label to the second structure and then binding the first label to the first structure.

[0033] In one aspect, the step of binding the first label to the first structure comprises directly or indirectly binding the first label to the first structure. The step of binding the first label to the first structure may comprise indirectly binding the first label to the first structure via one or more substances, for example, a molecule that specifically binds to the first structure, such as an antibody, an antibody fragment, a lectin, an aptamer, a ligand, a peptide, or a cyclic peptide. The step of binding the first label to the first structure may comprise indirectly binding the first label to the first structure via an antibody that specifically binds to the first structure. The step of binding the first label to the first structure may or may not involve washing the support after directly or indirectly binding the first label to the first structure. The step of binding the first label to the first structure may include (i) attaching an antibody capable of specifically binding to the first structure to the first structure, (ii) washing the support with a wash buffer, (iii) binding the first label to the antibody capable of specifically binding to the first structure, and / or (iv) washing the support with a wash buffer. The step of binding the first label to the first structure may include indirectly binding the first label to the first structure via an antibody that specifically binds to the first structure and a secondary antibody that specifically binds to the antibody. The step of binding the first label to the first structure may include (i) attaching an antibody capable of specifically binding to the first structure (e.g., an antibody that specifically binds to a virus capsid derived from a mouse) to the first structure; (ii) washing the support with a washing buffer; (iii) binding a secondary antibody that specifically binds to the antibody having the first label (e.g., an anti-mouse IgG antibody that specifically binds to the antibody derived from a mouse having Alexa Fluor (registered trademark) 647) to the antibody; and / or (iv) washing the support with a washing buffer.

[0034] In one embodiment, the step of binding the second label to the second structure comprises directly or indirectly binding the second label to the second structure. The step of binding the second label to the second structure may comprise indirectly binding the second label to the second structure via one or more substances, for example, a molecule that specifically binds to the second structure, such as an antibody, antibody fragment, lectin, aptamer, ligand, peptide, or cyclic peptide. The step of binding the second label to the second structure may comprise indirectly binding the second label to the second structure via a peptide that specifically binds to the second structure. The step of binding the second label to the second structure may or may not involve washing the support after directly or indirectly binding the second label to the second structure. The step of binding a second label to a second structure may involve binding a peptide (e.g., SYBR® Gold) that specifically binds to the second structure having a second label to the second structure, and / or (ii) not washing unbound peptides from the sample. The step of binding a second label to a second structure may involve (i) binding a peptide (e.g., SYBR® Gold) that specifically binds to the second structure having a second label to the second structure, and / or (ii) washing unbound peptides from the sample by using a wash buffer.

[0035] In one aspect, the method of the present invention includes a step of releasing the second structure from the first structure when the second structure is encapsulated in the first structure. The step of releasing the second structure from the first structure can be carried out, for example, by changing the temperature, heating, cooling, stirring, pipetting, using chemicals, changing the pH, or using an acid or alkali. Those skilled in the art can appropriately select the step of releasing the second structure from the first structure based on the properties, activity, strength, or amount of the "first structure" and "second structure." For example, heating may be carried out at about 75°C to about 95°C, about 80°C to about 90°C, or about 85°C. For example, heating may be carried out for about 5 minutes to about 25 minutes, about 10 minutes to about 20 minutes, or about 15 minutes. For example, heating may be carried out at about 85°C for about 15 minutes. The step of releasing the second structure from the first structure may be carried out before the step of binding the first label to the first structure. The step of releasing the second structure from the first structure may be performed after the step of binding the first label to the first structure. The step of releasing the second structure from the first structure may be performed before the step of binding the second label to the second structure. The step of releasing the second structure from the first structure may be performed after the step of binding the first label to the first structure and before the step of binding the second label to the second structure. For example, the step of releasing the second structure from the first structure makes it easier for the second label to bind to the second structure. For example, the step of releasing the second structure from the first structure allows the second label to bind to the second structure that was contained in the first structure. For example, the step of releasing the second structure from the first structure allows the second label to bind to the second structure more accurately or with greater precision.

[0036] In one embodiment, the method of the present invention includes a step of jointly detecting the amount of the bound first label and the amount of the bound second label. The step of jointly detecting the amount of the bound first label and the amount of the bound second label includes joint detection, for example, using one or more devices or detectors. The step of jointly detecting the amount of the bound first label and the amount of the bound second label includes joint detection, for example, using a single device or detector. For example, the step of jointly detecting the amount of the bound first label and the amount of the bound second label includes obtaining detection results for each of the "first label" and "second label." For example, when the "first label" and the "second label" are fluorescent dyes that emit different fluorescent signals, the step of jointly detecting the amount of the bound first label and the amount of the bound second label includes obtaining detection results for each fluorescent signal based on excitation and emission. When the "first label" is Alexa Fluor® 647, the detection result of the fluorescent signal may be obtained based on wavelengths of 652 nm (excitation) and / or 680 nm (emission). When the "second label" is SYBR® Gold, the detection result of the fluorescent signal may be obtained based on wavelengths of 495 nm (excitation) and / or 535 nm (emission), or based on wavelengths of 500 nm (excitation) and / or 535 nm (emission). When the "first label" is Alexa Fluor® 647 and the "second label" is SYBR® Gold, for example, one optical sensor, photodetector, microscope, device, or detector may be used to obtain detection results of fluorescent signals based on wavelengths of 652 nm (excitation) and / or 680 nm (emission) and detection results of fluorescent signals based on wavelengths of 495 nm (excitation) and / or 535 nm (emission) and / or 500 nm (excitation) and / or 535 nm (emission).Detecting the amount of bound first label and the amount of bound second label together, compared to detecting the amount of bound first label and the amount of bound second label separately (rather than together), can, for example, reduce the time or effort required to detect the amount of the first structure and the amount of the second structure, reduce the cost of detecting the amount of the first structure and the amount of the second structure, reduce detection errors in the amount of the first structure and the amount of the second structure, eliminate the need to purify the first structure or the second structure from a sample containing contaminants, or enable the amount of the first structure and the second structure to be detected at low concentrations.

[0037] In one embodiment, the method of the present invention includes a step of calculating or determining the amount (or concentration) of the first structure and the amount (or concentration) of the second structure based on the amount (or concentration) of the bound first label and the amount (or concentration) of the bound second label. Those skilled in the art can appropriately calculate or determine the amount (or concentration) of the first structure and the amount (or concentration) of the second structure based on the characteristics of the first structure, the second structure, the label, the device, the detector, or the detection results. For example, the step of calculating or determining the amount (or concentration) of the first structure and the amount (or concentration) of the second structure may include creating a calibration curve of the amount (or concentration) of the first label and the amount (or concentration) of the first structure and / or a calibration curve of the amount (or concentration) of the second label and the amount (or concentration) of the second structure. For example, a calibration standard (e.g., a commercially available standard, standard solution, or standard sample) may be used to create the calibration curve. Those skilled in the art can appropriately determine the standards to be used for the calibration curve based on the characteristics of the first construct, the second construct, the label, the device, the detector, or the detection results. For example, a standard for the calibration curve may be set for each of the first construct and / or the second construct to be calculated or determined. For example, even if the lengths of the first construct and / or the second construct and the standard are different, the amount (or concentration) of one or more first constructs and / or the amount (or concentration) of one or more second constructs can be calculated or determined by performing a computational correction. For example, even if the lengths of the second construct and the calibration curve standard are different, the amounts (or concentrations) of two or more second constructs can be calculated or determined by using a single type of calibration curve standard and performing a computational correction (e.g., based on the correlation between DNA length and fluorescence intensity).

[0038] In one embodiment, when a second structure is encapsulated in a first structure, the amount (or concentration) of the first structure encapsulating the second structure (e.g., a viral capsid containing nucleic acid) and / or the amount (or concentration) of the first structure not encapsulating the second structure (e.g., a viral capsid not containing nucleic acid) can be determined based on the calculated or determined amount (or concentration) of the first structure and the second structure. For example, the amount (or concentration) of the first structure encapsulating the second structure (e.g., a viral capsid containing nucleic acid) can be determined based on the calculated or determined amount (or concentration) of the second structure. For example, the amount (or concentration) of the first structure not encapsulating the second structure (e.g., a viral capsid not containing nucleic acid) can be determined by subtracting the calculated or determined amount (or concentration) of the second structure from the calculated or determined amount (or concentration) of the first structure. Based on the calculated or determined amount (or concentration) of the first structure and the amount (or concentration) of the second structure, the ratio of first structures containing the second structure (e.g., viral capsids containing nucleic acid) to first structures not containing the second structure (e.g., viral capsids not containing nucleic acid) can be evaluated or determined. For example, the percentage (proportion) of first structures containing the second structure (e.g., viral capsids containing nucleic acid) can be determined by dividing the calculated or determined amount (or concentration) of the second structure by the calculated or determined amount (or concentration) of the first structure. For example, based on this percentage (proportion), the percentage (proportion) of first structures not containing the second structure (e.g., viral capsids not containing nucleic acid) can be determined. For example, based on the calculated or determined amount (or concentration) of the first structure and the second structure, the amount (or concentration) of active viral vector (complete particles) and / or the amount (or concentration) of inactive viral vector (empty particles) can be determined. For example, the ratio of full particles to empty particles can be estimated or determined based on the calculated or determined amount (or concentration) of the first structure and the amount (or concentration) of the second structure.

[0039] In one embodiment, the method of the present invention may use ELISA (enzyme-linked immunosorbent assay), which is an immunological assay. The method of the present invention is an adaptation of ELISA, which is an immunological assay, and is called Dual Fluorescence-Linked Immunosorbent Assay (dFLISA).

[0040] In one embodiment, the method of the present invention may include detecting the amount (or concentration) of one or more additional structures (e.g., a third structure and / or a fourth structure) in addition to detecting the amount (or concentration) of the first structure and the amount (or concentration) of the second structure. For example, a sample, a container, or a well in a plate may contain one or more additional structures (e.g., the third structure and / or the fourth structure) in addition to the first structure and the second structure. For example, the step of detecting the amount (or concentration) of one or more additional structures (e.g., the third structure and / or the fourth structure) may be the same as the method or step of detecting the amount (or concentration) of the first structure and the amount (or concentration) of the second structure described herein.

[0041] Unless otherwise specified, the terms used herein are those commonly used in the art.

[0042] The present invention will be explained in more detail by showing the following examples, but it should not be construed that the scope of the present invention is limited to these examples.

[0043] List of materials and equipment used

[0044] Example 1

[0045] Preparation of AAV VHH antibody: The reagents were weighed out and mixed in a 15 mL tube (100-fold dilution). An example is shown below.

[0046] Coating of AAV VHH antibody onto plates: 100 μL of diluted AAV VHH antibody was added to each well. An example is shown below. A sticker was attached to the top of the plate and pressed firmly with a spatula. The plate was incubated at 4°C for 16 hours.

[0047] Preparation of 1x PBS: Weigh out the reagents into a 500 mL glass bottle and mix them. An example is shown below. The vial was shaken to mix well.

[0048] Preparation of 1% TWEEN20 in 1x PBS: The reagents were weighed out and mixed in a 15 mL tube. An example is shown below. The tube was shaken and mixed well by vortexing.

[0049] Preparation of Wash buffer (0.05% TWEEN20 in 1x PBS, pH 7.4): The reagents were weighed and mixed in a 500 mL glass bottle. An example is shown below. The vial was shaken to mix well.

[0050] Preparation of Blocking buffer and Dilution buffer (1% BSA in 0.05% TWEEN20 of 1x PBS, pH=7.0) The reagents were weighed and mixed in a 50 mL tube. An example is shown below. Mix by vortexing.

[0051] Washing of unbound VHH antibodies The plate was removed from the refrigerator (4°C). The VHH solution in each well of the plate was removed using a multichannel pipette. 200 μL of wash buffer was added to each well, and the plate was then turned upside down and the wash buffer was removed using a Kimtowel. This procedure was repeated three times.

[0052] Blocking of the plate: 200 μL of blocking buffer was added to each well. A seal was attached to the top of the plate and pressed in place with a spatula. The plate was incubated at 37°C for 1 hour. After incubation, the blocking buffer in each well was removed using a multichannel pipette. 200 μL of wash buffer was added to each well, and the plate was then turned upside down and the wash buffer was removed using a Kimtowel. This procedure was repeated three times.

[0053] Preparation of AAV standard solution and sample solution <Preparation of standard curve solution> The AAV sample for the standard curve was diluted in a 1.5 mL microtube. An example is shown below. The diluted AAV sample for the standard curve was serially diluted as follows to prepare the standard curve samples (SD1 to SD7). <Preparation of sample solution for measurement> The AAV sample for measurement was diluted in a 1.5 mL microtube. An example is shown below.

[0054] Addition of sample AAV 100 μL of sample AAV was added to each well. An example is shown below. * B: Wash buffer SD: Standard curve sample SP: Measurement sample A sticker was attached to the top of the plate and pressed in place with a spatula. The plate was incubated at 37°C for 1 hour. After incubation, the AAV solution in each well was removed with a multichannel pipette. 200 μL of wash buffer was added to each well, and the plate was then turned upside down and the wash buffer was removed with a Kimtowel. This procedure was repeated three times.

[0055] Preparation of anti-AAV8 antibody (ADK8) The reagents were weighed out and mixed in a 15 mL tube (50x). An example is shown below. The tube was shaken to mix well.

[0056] Addition of anti-AAV8 antibody (ADK8): 100 μL of prepared ADK8 was added to each well. A seal was attached to the top of the plate and pressed in place with a spatula. The plate was incubated at 37°C for 1 hour. After incubation, the AAV solution in each well was removed using a multichannel pipette. 200 μL of wash buffer was added to each well, and the plate was then turned upside down and the wash buffer was removed using a Kimtowel. This procedure was repeated three times.

[0057] Preparation of Goat Anti-Mouse IgG H&L (Alexa Fluor 647) The reagents were weighed out and mixed in a 15 mL tube (500-fold dilution). An example is shown below. The tube was gently shaken to mix well, and the 15 mL tube was covered with aluminum foil.

[0058] Addition of Goat Anti-Mouse IgG H&L (Alexa Fluor 647) 100 μL of Goat Anti-Mouse IgG H&L (Alexa Fluor 647) was added to each well. A sticker was attached to the top of the plate and pressed into place with a spatula. The plate was incubated at 37°C for 1 hour in the dark at 300 rpm. After incubation, the AAV solution in each well was removed using a multichannel pipette. 200 μL of wash buffer was added to each well, and the plate was then inverted and the wash buffer was removed using a Kimtowel. This procedure was repeated three times.

[0059] Genome extraction: 100 μL of 1x PBS was added to each well. A seal was attached to the top of the plate and pressed in place with a spatula. The plate was incubated at 85°C for 15 minutes. After incubation, the plate was covered with aluminum foil and left to stand at room temperature for 5 minutes.

[0060] Preparation of SYBR Gold: The reagents were weighed out and mixed in a 15 mL tube (1000-fold dilution). An example is shown below. The tube was gently shaken to mix well, and the 15 mL tube was covered with aluminum foil.

[0061] Addition of SYBR Gold: 10 μL of SYBR Gold was added to each well. The plate was gently tilted to mix. The plate was covered with aluminum foil and left to stand at room temperature for 5 minutes.

[0062] Fluorescence intensity was measured using a SpectraMax i3x. Data analysis: A four-parameter logistic regression was performed on the results of the calibration curve solution to create a calibration curve. The Capsid concentration and nucleic acid concentration of each sample were determined from the calibration curve. Measurement conditions The results are shown in Figure 2.

[0063] Example 2 A test was performed in the same manner as in Example 1, except that AAV8 and anti-AAV8 antibody (ADK8) were replaced with AAV2 and anti-AAV2 antibody (A20) shown in the table below. The results are shown in Figure 3.

[0064] Example 3: AAV8 and anti-AAV8 antibody (ADK8) were tested in the same manner as in Example 1, using a mixture of AAV2 and AAV8 as shown in the table below, and anti-AAV2 antibody (A20) and anti-AAV8 antibody (ADK8). The results are shown in Figure 4. A dose-response curve was obtained for the total number of AAV8 capsids. Detection of antibodies against individual AAV serotypes (AAV8 & AAV2) was confirmed by the method of the present invention (dFLISA).

[0065] Example 4 A test was performed in the same manner as in Example 1, except that SYBR Gold was replaced with QuantiFluor, and proteins were detected using antibodies labeled with HRP (Horse Radish Peroxidase) and absorbance measurements were performed in the presence of TMB (3,3',5,5'-tetramethylbenzidine). The results are shown in Figure 5.

[0066] Example 5: A test was performed in the same manner as in Example 2 using AAV2 containing ssDNA and AAV2 containing scDNA. The results are shown in Figure 6. The fluorescence intensity of AAV2 scDNA was approximately 1.4-1.6 times that of AAV2 ssDNA. Because scDNA is a long-chain DNA, appropriate correction for DNA length may enable quantification independent of DNA length.

[0067] Example 6 Measurement of DNA fluorescence intensity was performed in the same manner as in Example 2, using conventional wavelengths of 495 nm and 535 nm or wavelengths of 500 nm and 535 nm (optimized conditions) developed by the inventors. The results are shown in Figure 7. The signal background of the sample was equivalent to or higher under the optimized conditions compared to the conventional wavelengths.

[0068] Example 7 A test was performed in the same manner as in Example 2 using a clear plate (Nunc MaxiSorp™ flat-bottom clear 96-well plate) and a black plate (The Nunc MaxiSorp™ flat-bottom black 96-well plate). The results are shown in Figure 8. The fluorescence intensity of the sample showed a higher response in the black plate compared to the clear plate. This result suggests that the black microplate is suitable for providing a signal suitable for the method of the present invention.

[0069] Example 8: To confirm whether the method of the present invention (dFLISA) can be used to analyze unpurified samples without purification, a spike recovery test was performed. The recovery rate was within ±25% of the predicted value, meeting the criteria. This indicates that dFLISA results are less susceptible to the influence of contaminants contained in unpurified samples. This demonstrates that dFLISA is an excellent method for evaluating unpurified AAV samples. The dFLISA method is a valuable and novel method that can be used to accurately quantify the titer of unpurified samples. It is unique in that it can directly quantify the full and empty capsid concentrations and FP / EP ratios of unpurified samples. The results are shown in Figure 9.

[0070] dFLISA can measure capsid and genome titers of crude samples. Capsid titers measured by dFLISA were comparable to those measured by ELISA. However, genome titer results by dFLISA were higher than those by dPCR. Considering the high recovery rate in spike-recovery experiments, dFLISA results are considered reliable. Previous studies have shown that dPCR can be affected by impurity interference, so dFLISA may be a more accurate method for measuring the concentration of AAV genome material in crude samples compared with the combination of ELISA and dPCR. The results are shown in Figure 10.

[0071] The results of dFLISA suggest that it is less susceptible to impurities present in unpurified samples and is a reliable analytical technique for AAV vector particle analysis.

[0072] Comparison of quantification of unpurified samples by dFLISA and other methods. The dFLISA method was as described above. In these experiments, AAV8-Lot1 was purified to a final concentration of 2.01 x 10 11 cp / mL and 1.81 x 10 11 The AAV8-Lot2 was diluted 60-fold with 1x PBS (containing 0.05% Tween 20) to a final concentration of 5.36 x 10 vg / mL. It was then serially diluted 1:2 to prepare a standard for the calibration curve. For the spiked sample, AAV8-Lot2 was concentrated by ultracentrifugation to a final concentration of 5.36 x 10 13 cp / mL, 4.75 x 10 13 The concentrations were adjusted to vg / mL and then diluted with 1 x PBS (containing 0.05% Tween 20) as follows: High concentration (Spike H): 1.07 x 10 11 cp / mL and 9.50 x 10 10 vg / mL, medium concentration (Spike M): 7.15 x 10 10 cp / mL and 6.33 x 10 10 vg / mL, low concentration (Spike L): 5.36 x 10 10 cp / mL and 4.75 x 10 10vg / mL. Each spike sample solution was added to an unknown concentration unpurified sample (AAV8-Lot4) at a volume ratio of 1:1 and mixed, and 100 μL of the prepared spike ratio sample solution was added to each well of the plate. Analysis was performed in duplicate. Recovery was evaluated using the following formulas: Mixed spike (HM) = (1 / 2) (unpurified + spike H) - (1 / 2) (unpurified + spike M) (Equation 3) Mixed spike (HM) = (1 / 2) (unpurified + spike H) - (1 / 2) (unpurified + spike L) (Equation 4). The target recovery rate (%) was within ±25%.

[0073] Quantification of capsid and genome titers in crude samples. dFLISA was performed as described above. AAV8-Lot1 was diluted 60-fold in 1x PBS (containing 0.05% Tween 20) to a final concentration of 2.01 x 10 11 cp / mL and 1.81 x 10 11 The standard curve was prepared by serially diluting the standard at a ratio of 1:2 to 2. Unpurified AAV8 samples of unknown concentrations were then analyzed using dFLISA (n=2) as detailed in the previous section.

[0074] Example 9: Fluorescence intensity in genome quantification using fluorescent dyes varies depending on genome length, and this is also relevant to dFLISA. When the correlation between fluorescence intensity normalized by concentration was compared using DNA of different genome lengths, a correlation between genome length and fluorescence intensity was observed. The results are shown in Figure 11. Furthermore, when the fluorescence intensity of AAV vectors with different genome lengths was compared (Table 22), the fluorescence intensity was higher in samples with longer genome lengths, and the ratio of genome length to fluorescence intensity was similar to that shown in Figure 11. These results confirmed the validity of dFLISA as a method for evaluating the genomes of AAV vectors with various nucleic acids. In addition, even if the genome length differs from that of a standard AAV vector, genome length can be corrected by calculation, demonstrating that it is not necessary to prepare a standard AAV for each AAV with different genome lengths.

[0075] The fluorescence intensity of ssDNA from 1100 bp to 5100 bp was measured using an ssDNA 7K ladder (PerkinElmer, Waltham, MA, USA). First, the ssDNA ladder marker solution was appropriately diluted with Milli-Q and then loaded onto a 1% agarose gel. Next, 10 μL of sample was added to 2 μL of EzApplyDNA (6x loading buffer), mixed thoroughly by pipetting, and 10 μL of the mixture was loaded onto the gel. Electrophoresis was performed at 70 V for 45 minutes. After electrophoresis, the gel was stained and washed according to the manufacturer's instructions. SYBR Gold Nucleic Acid Gel staining solution was used to stain the gel. Quantitative analysis of brightness density within the stained gel was performed.

[0076] Mass photometry (MP) measurements were then performed. Prior to MP measurements, the ssDNA ladder solution was diluted and analyzed at room temperature. Data analysis was performed using DiscoverMP.

[0077] The fluorescence intensity of each ssDNA band obtained from the five agarose gel electrophoresis (AGE) analyses was then divided by the MP area (%) and plotted against the ssDNA length. The expected intensity of an AAV vector carrying both scDNA (3681 bp) and ssDNA (2521 bp) was also estimated from the curves.

[0078] The fluorescence intensity of AAV containing ssDNA and scDNA was examined using dFLISA. AAV2-Lot1 containing ssDNA was diluted to 7.70 x 10 10 cp / mL and 6.41 x 10 10 The AAV2-Lot2 containing scDNA was diluted 100-fold in 1x PBS (containing 0.05% Tween 20) to a final concentration of 2.11 x 10 vg / mL. A standard curve was prepared by serial dilution in 1:2 ratio steps. Similarly, AAV2-Lot2 containing scDNA was diluted 100-fold to a final concentration of 2.11 x 10 11 cp / mL and 1.93 x 10 11The fluorescence intensity ratios for ssDNA AAV8 and scDNA AAV2 were measured using dFLISA and compared with the fluorescence intensity ratios calculated from the curves.

Claims

1. A method for detecting an amount of a first structure and an amount of a second structure, the method comprising the steps of: binding a first label to the first structure; releasing the second structure from the first structure; binding a second label to the second structure; and jointly detecting the amount of bound first label and the amount of bound second label, wherein the second structure is contained within the first structure, and the first label and the second label are different, although they can be detected together.

2. The method of claim 1, further comprising the step of washing away the first label that is not bound to the first structure.

3. The method of claim 2, wherein the step of washing away the first label not bound to the first structure is performed after the step of binding the first label to the first structure and before the step of releasing the second structure from the first structure and the step of binding the second label to the second structure.

4. The method of claim 1, further comprising the step of fastening the first structure to a support.

5. The method of claim 1, wherein the first structure is composed of a protein, a lipid or a polymer, or a combination thereof.

6. The method of claim 1, wherein the first structure is selected from the group consisting of a viral particle, a viral capsid, a liposome, a lipid nanoparticle (LNP), and a polymeric particle.

7. The method of claim 6, wherein the virus is selected from the group consisting of adeno-associated virus (AAV), retrovirus, lentivirus, and adenovirus.

8. The method of claim 1, wherein the second structure is comprised of a nucleic acid, a protein or a chemical compound, or a combination thereof.

9. The method of claim 8, wherein the second structure is selected from the group consisting of DNA, single-stranded DNA (ssDNA), self-complementary DNA (scDNA), RNA, miRNA, lncRNA, a peptide, an antibody, a detection compound, and a drug.

10. The method of claim 1, wherein the first label and the second label are fluorescent dyes or radioactive labels.

11. The method of claim 1, wherein the step of binding the first label to the first structure comprises indirect binding via a molecule that specifically binds to one or more of the first structures, such as an antibody, an antibody fragment, a lectin, an aptamer, a ligand, a peptide, or a cyclic peptide, or comprises indirect binding via said molecule that specifically binds to the first structure and a secondary antibody that specifically binds to said molecule.

12. The method of claim 1, wherein the step of jointly detecting the amount of bound first label and the amount of bound second label comprises jointly detecting using a single device or detector.

13. The method of claim 1, wherein the amount of the first structure and the amount of the second structure are calculated or determined based on the amount of the bound first label and the amount of the bound second label.

14. The method of claim 1, further comprising calculating or determining a ratio of first structures that contain second structures to first structures that do not contain second structures.

15. A method for assessing the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid, the method comprising the steps of: immobilizing the viral capsid on a support; indirectly binding a first label to the viral capsid via an antibody that binds to the viral capsid; washing away unbound first label; releasing nucleic acid from the viral capsid; binding a second label to the released nucleic acid; detecting the amount of bound first label and the amount of bound second label together; and calculating or determining the ratio of viral capsids containing nucleic acid to viral capsids not containing nucleic acid based on the amount of bound first label and the amount of bound second label, wherein the nucleic acid is encapsulated in the viral capsid; and the first label and the second label can be detected together but are different.

16. A detection kit comprising: a first label on a first structure; a second label on a second structure; and instructions for detecting the amount of bound first label and the amount of bound second label together, wherein the second structure is contained within the first structure; and wherein the first label and the second label are different but can be detected together.

Citation Information

Patent Citations

  • Analytically separating method of virus

    JP1996228800A

  • Expression cloning process for discovering, characterizing and isolating gene coding for polypeptide having previously decided specific characteristic

    JP2000189173A

  • Method for producing multicolor quantum dot-labeled beads and conjugates thereof

    JP2005508493A

  • Assay

    JP2017029151A

  • Systems and methods for detecting infectious diseases

    JP2022002529A